James P Flynn bought $98k of LITS
director at MEI Pharma, Inc.. 70,000 shares at an average of $1.40, traded Dec 19, 2025, filed Dec 22, 2025.
Score components
- +15RoleDirector
- +10Trade size$98k at market
- +10Relative to holdingsHoldings up 233%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.4%, 3m -16.3%, 6m -36.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-328666, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | POpen-market purchase Common Stock | +70,000 | $1.40 | $98k | 100,000 | Dec 22, 2025 |
Related signals
Other insiders at MEI Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | LITSbuy MEI Pharma, Inc. | James P Flynn director | $21k 25,000 shares | +25% | |
| 41Moderate | LITSsell MEI Pharma, Inc. | Alexander Schornstein owner | $946k 690,611 shares | -16% | |
| 25Weak | LITSbuy MEI Pharma, Inc. | James P Flynn director | $23k 12,100 shares | +68% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.